How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

from Rx for Biotech · host Podcast Host Chris Leidli

In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.

Episode metadata supplied by the publisher feed · Published Nov 11, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

0:00 28:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Rx for Biotech?

This episode is 28 minutes long.

When was this Rx for Biotech episode published?

This episode was published on November 11, 2025.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!